Forbes · Rashi Shrivastava ·

Albert Invent, which launched an AI model trained on chemical patents and data about 15M molecules, raised a $55M Series B, a source says at a $340M valuation

Scientists at manufacturing conglomerates like Kenvue and Henkel use Albert Invent's AI tools to design experiments.

AI Venture Capital

In this story Albert Invent

Lead Source

Forbes — Albert Invent, which launched an AI model trained on chemical patents and data about 15M molecules, raised a $55M Series B, a source says at a $340M valuation ↗

How this story grew

Coverage · 0 Discussion · 0

Oct 14Oct 15

More

Albert Invent: Albert Invent

Discussion

@rashishrivast18

Related stories

Bloomberg: Isomorphic Labs, an AI drug discovery startup spun out of Google DeepMind, is in early talks to raise funds at a valuation of at least $40B

TechCrunch: Outmarket, which uses AI to help insurance agencies and brokers automate their tedious paperwork, raised a $34.5M Series B, a source says at a $335M valuation

TechCrunch: Colorado-based Enveda, which uses AI to discover new drugs in the natural world, raised a $311M Series E at a $2B valuation, double its valuation a year ago

Reuters: Shanghai-based Anew Labs, a ByteDance spinoff using AI for drug discovery, raised $290M from HSG, IDG Capital, and others at a $1.5B valuation

GamesBeat: Astromech, which uses genomic data to build predictive AI models of biological change, raised $20M at a $3.8B valuation, bringing its total funding to $60M

Discuss with AI

ChatGPT ↗ Claude ↗

← Back to TechSnif